Objective This study aimed to systematically analyze the epidemiological characteristics of six major musculoskeletal disorders (MSDs) among postmenopausal women globally from 1990 to 2021, with a focus on the spatiotemporal distribution patterns of disease prevalence and associated disability-adjusted life years (DALYs).

Methods Utilizing the 2021 Global Burden of Disease (GBD) database, we examined six MSDs in postmenopausal women: rheumatoid arthritis, osteoarthritis, low back pain, neck pain, gout, and other musculoskeletal disorders. Age-standardized rates (ASRs) were calculated using internationally recognized methods, and estimated annual percentage changes (EAPCs) were employed to assess temporal trends in disease burden. The analysis incorporated considerations of age structure, sociodemographic index (SDI), and various risk factors.

Results From 1990 to 2021, the global burden of MSDs among postmenopausal women showed a persistent increase, with marked heterogeneity across disease subtypes and geographical regions. Osteoarthritis represented the predominant disease burden, while gout exhibited the most rapid growth despite its lower baseline prevalence. Notably, low back pain was the only subtype demonstrating a declining trend. The burden of MSDs shifted from high-SDI regions to developing areas, with middle-SDI countries emerging as new priorities for intervention. Older age groups bore a disproportionately high disease burden, and obesity was identified as the leading risk factor driving disease progression, whereas tobacco control measures showed positive effects. Projections indicated that MSD burden will continue to rise with population aging, necessitating tailored prevention and management strategies to address this major public health challenge.

Conclusion The prevalence of MSDs among postmenopausal women continues to rise, underscoring its profound impact on global health in aging female populations. To address this challenge, a multidimensional intervention approach is required, including: (1) enhanced early screening and standardized management of MSD-related risk factors; (2) personalized lifestyle interventions based on individual BMI levels; and (3) implementation of differentiated public health policies tailored to population-specific characteristics. The comprehensive adoption of these measures will help improve musculoskeletal health in postmenopausal women and reduce the overall disease burden attributable to MSDs.

The authors have declared no competing interest.

This study was supported by the National Natural Science Foundation of China (No. 82402849, to P.Ding; No. 82272474, to Y.Gao)

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

https://ghdx.healthdata.org/gbd-2021

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Funding: The Global Burden of Disease Study is funded by the Bill & Melinda Gates Foundation. This study was supported by the National Natural Science Foundation of China (No. 82402849, to P.Ding; No. 82272474, to Y.Gao)

All data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscript All data produced are available online at https://ghdx.healthdata.org/gbd-2021